Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Development of the Simulation Curriculum and AI-incorporated Assessment Tool for Transesophageal Echocardiography Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027 National Taiwan University HospitalNot specified NCT06567912
  2. Notable: Supersaturated Hydrogen-Rich Water for Outpatients With Persistent Excess Weight Primary completion pushed from Jan 15, 2027 to Oct 15, 2027 Center for Health Sciences, SerbiaNot applicable NCT07410065
  3. Notable: HEMImprove 1.0 in Children and · Unilateral Cerebral Palsy Primary completion pushed from Feb 1, 2027 to Feb 1, 2028 University of Castilla-La ManchaNot applicable NCT07041944
  4. Notable: TRIAGE-GS · Towards Reducing Inefficiencies Affecting Genetics Encounters Through Genome Sequencing Primary completion pushed from Dec 2026 to Mar 2028 The Hospital for Sick ChildrenNot applicable NCT06935019
  5. Notable: Effect In Spinal Cord Electrical Stimulation for Pain Primary and study completion pushed from Jun 30, 2027 to Jun 30, 2028 Sahlgrenska University HospitalNot applicable NCT06585033
  6. Notable: Renal MRI and Advanced Biochemical Markers to Predict Progression in DKD Patients Treated With SGLT2i Primary and study completion pushed from Aug 2027 to Apr 2028 Mario Negri Institute for Pharmacological ResearchNot applicable NCT07270198
  7. Notable: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer Primary completion pushed from Jun 1, 2026 to May 1, 2027 Galzu Institute of Research, Teaching, Science and Applied TechnologyNot applicable NCT06045572
  8. Notable: Systematic Oral Feeding Education Program Primary and study completion pushed from Dec 19, 2025 to Dec 19, 2026 National Taiwan University HospitalNot applicable NCT06763497
  9. Notable: TL117 · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase changed: Phase 1/2 → Phase 1 Suzhou Junde Biotechnology Co., LtdPhase 1 NCT04843098
  10. Notable: Berobenatide · Urine Leakage and With Obesity or Overweight (VESPER-SUI) Recruitment opened PfizerPhase 3 NCT07932925
  11. Notable: 177Lu-NYM032 Injection · Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruitment opened Norroy Bioscience Co., LTDPhase 3 NCT07795268
  12. Notable: Zigakibart + Atrasentan · Primary IgA Nephropathy Recruitment opened Novartis PharmaceuticalsPhase 3 NCT07850752
  13. Notable: Efgartigimod · Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) Recruitment opened argenxPhase 2 NCT07760818
  14. Notable: Single-agent Therapy of BR113 for Injection · Advanced Solid Tumors Recruitment opened BioRay Pharmaceutical Co., Ltd.Phase 1 NCT07753590
  15. Notable: ABI-6250 · Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function Recruitment opened Assembly BiosciencesPhase 1 NCT07850999
  16. Notable: Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 · IRM Recruitment opened Norroy Bioscience Co., LTDPhase 1 NCT07768306
  17. Notable: Nutritional Supplementation on Actinic Purpura: A Pilot Study Trial status changed: Suspended → Withdrawn Standard Process Inc.Not applicable NCT06840574
  18. Notable: GRACE-DE · Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) Recruitment opened AstraZenecaNot specified NCT07882212
  19. Notable: BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4 Recruitment opened SynchroHealth LLCNot applicable NCT07421648
  20. Notable: Pediatric Sleep Study Recruitment opened Olly, PBCNot applicable NCT07932938
  21. Notable: IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Recruitment opened Shanghai Gynecologic Oncology GroupPhase 1 NCT07674615
  22. Notable: Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy · Atrial Fibrillation Recruitment opened China National Center for Cardiovascular DiseasesNot applicable NCT07762742
  23. Notable: Metabolic Changes Associated With Weight Gain After Treatment of Achalasia Recruitment opened Assaf-Harofeh Medical CenterNot specified NCT07334639
  24. Notable: Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial Recruitment opened Sichuan Cancer Hospital and Research InstitutePhase 2 NCT07775040
  25. Notable: Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery Recruitment opened Mayo ClinicPhase 4 NCT07570940